Development of single-domain antibodies (nanobodies) from Llama (Vicugna pacos) and therapeutic C7C peptides against protein S of SARS-CoV-2

SARS-CoV-2 remains a global threat because vaccines are not providing complete protection against new variants. Aa a result, there is a unmet need for effective COVID-19 treatments. Treatment with antibodies is an effective choice. Single-domain antibodies (nanobodies) derived from camelid animals (e.g. llamas) have a high potential for treating viral infections. Another promising molecules with therapeutic potential are small peptides (7-12 amino acids). Nanobodies and peptides that bind to the receptor binding domain (RBD) of the virus can effectively neutralize this virus. Further, small size, stability and easy production of nanobodies and peptides make them more suitable for drug development. In this project we aim to produceseveral nanobodies from llama and 7-mer peptides using phage display technology. We further aim to confirm their virus neutralization abilityand test their non-toxicity. We believe that nanoantibodies and peptides will have high potential to be transformed into therapeutics in the near future.